Hosted on MSN13d
Biogen CEO sees no burning need for more acquisitions
SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the ...
Pharma digs in on changes it wants from Trump administration
The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...
Biopharma industry eyes 2025 bounceback, grapples with uncertainty over Trump return
The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over ...
U.S. News & World Report12d
Pharma Digs in on Changes It Wants From Trump Administration
Pharma Digs in on Changes It Wants From Trump Administration By Deena Beasley SAN FRANCISCO (Reuters) - The pharmaceutical industry, grappling with new government limits on drug prices ...
Reuters15d
Biopharma industry eyes 2025 bounceback, grapples with uncertainty over Trump return
SAN FRANCISCO, Jan 14 (Reuters) - The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over what President-elect Donald Trump's ...